Asset profile
Psilocybin (COMP360)
Small molecule
Evidence outlook · lead readout
NCT05624268 · Treatment Resistant Depression
The completed lead evidence has the design features that historically survive confirmatory trials: randomized, controlled, and adequately powered against a prespecified clinically accepted endpoint.
NCT05624268: This was a randomized, quadruple-blind, placebo-controlled trial with 258 participants, using change in a standard clinician-rated depression scale as the primary measure. The sponsor reports a statistically significant difference favoring COMP360 over placebo at week 6.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Also in development:Post-Traumatic Stress Disorder · Phase 3
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
66 competitors in this universe: 7 direct rivals (same mechanism and indication), 0 same-class, 59 same-indication; 9 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Psilocybin (COMP360): this drug | Phase 3 | Small molecule | 5-HT2A receptor | ||
| CYB003 | Phase 3 | Small molecule | 5-HT2A receptor | ||
| Lysergide Tartrate (LSD) (DT120) | Phase 3 | Small molecule | 5-HT2A receptor | ||
| BPL-003 (mebufotenin Benzoate) | Phase 2 | Small molecule | 5-HT2A receptor | ||
| Bretisilocin | Phase 2 | Small molecule | 5-HT2A receptor | ||
| Mebufotenin (5-MeO-DMT) (GH001) | Phase 2 | Small molecule | 5-HT2A receptor | ||
| VLS-01 | Phase 2 | Small molecule | 5-HT2A receptor | ||
| ELE-101 | Phase 1/2 | Small molecule | 5-HT2A receptor | ||
| Brexpiprazole (Rexulti) | Approved | Small molecule | Dopamine D2/D3 and serotonin 5-HT1A receptor | ||
| Cariprazine (Vraylar) | Approved | Small molecule | Dopamine D3/D2 receptor (partial agonist) | ||
| Cyclobenzaprine (Tonmya) | Approved | Small molecule | 5-HT2A, α1-adrenergic, H1-histaminergic, and M1-muscarinic acetylcholine receptors (functional antagonism) | ||
| Dextromethorphan / Bupropion (Auvelity) | Approved | Small molecule | sigma-1/NMDA | ||
| Esketamine (Spravato) | Approved | Small molecule | NMDA receptor | ||
| Lumateperone (Caplyta) | Approved | Small molecule | Serotonin 5-HT2A / dopamine D1-D2 receptor | ||
| Olanzapine / Fluoxetine (Symbyax) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist); serotonin transporter (reuptake inhibitor) | ||
| Solriamfetol (Sunosi) | Approved | Small molecule | Dopamine/norepinephrine transporter |
…and 51 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
1 further head-to-head pair is tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(48 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (5)
December 2026 (5)
What to watch
What to watch
What to watch
What to watch
What to watch
2027 (16)
January 2027 (1)
What to watch
February 2027 (1)
What to watch
March 2027 (1)
What to watch
April 2027 (2)
June 2027 (2)
July 2027 (1)
What to watch
August 2027 (1)
What to watch
October 2027 (3)
What to watch
What to watch
What to watch
November 2027 (1)
What to watch
December 2027 (3)
What to watch
What to watch
What to watch
2028 (14)
March 2028 (4)
What to watch
What to watch
What to watch
What to watch
April 2028 (1)
What to watch
May 2028 (2)
June 2028 (1)
What to watch
July 2028 (2)
September 2028 (1)
What to watch
November 2028 (1)
What to watch
2029 (7)
January 2029 (1)
What to watch
April 2029 (2)
September 2029 (1)
What to watch
December 2029 (3)
What to watch
What to watch
What to watch
2030 (4)
February 2030 (1)
What to watch
June 2030 (1)
What to watch
July 2030 (1)
What to watch
December 2030 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.